Patents by Inventor Dan Mourich

Dan Mourich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070111962
    Abstract: A method and compound for suppressing an immune response in a mammalian subject, for the treatment or prevention of an autoimmune condition or transplantation rejection are disclosed. The compound is an antisense oligonucleotide analog compound having a targeting sequence complementary to a preprocessed CTLA-4 mRNA region identified by SEQ ID NO: 1, spanning the splice junction between intron 1 and exon 2 of the preprocessed mRNA of the subject. The compound is effective, when administered to a subject, to form within host cells, a heteroduplex structure (i) composed of the preprocessed CTLA-4 mRNA and the oligonucleotide compound, (ii) characterized by a Tm of dissociation of at least 45° C., and (iii) resulting in an increased ratio of processed mRNA encoding ligand-independent CTLA-4 to processed mRNA encoding full-length CTLA-4.
    Type: Application
    Filed: November 8, 2006
    Publication date: May 17, 2007
    Inventors: Dan Mourich, Patrick Iversen, Dwight Weller
  • Publication number: 20070037764
    Abstract: The invention provides antisense antiviral compounds and methods of their use in inhibition of growth of human immunodeficiency virus-1 (HOV-1), as in treatment of a viral infection. The antisense antiviral compounds have morpholino subunits linked by uncharged phosphorodiamidate linkages interspersed with cationic phosphorodiamidate linkages. An exemplary embodiment of the invention provides an antisense compound directed to the HIV Vif gene, causing the production of defective HIV- 1 virions in an infected individual.
    Type: Application
    Filed: May 11, 2006
    Publication date: February 15, 2007
    Inventors: Dan Mourich, Patrick Iversen, Richard Bestwick, Dwight Weller
  • Publication number: 20060276425
    Abstract: A method and composition for inducing human dendritic cells to a condition of reduced capacity for antigen-specific activation of T cells, and, in mature dendritic cells, increased production of extracellular IL-10 is disclosed. A population of dendritic cells is exposed to a substantially uncharged antisense compound, including partially positively charged, containing 12-40 subunits and a base sequence effective to hybridize to an expression-sensitive region of a preprocessed or processed human CD86 transcript identified, in its processed form, by SEQ ID NO:33, to form a duplex structure between said compound and transcript having a Tm of at least 45° C. Formation of the duplex blocks expression of full-length CD86 in said cells, which in turn leads to reduced capacity for antigen-specific activation of T cells, and, in mature dendritic cells, increased production of extracellular IL-10.
    Type: Application
    Filed: May 11, 2006
    Publication date: December 7, 2006
    Inventors: Dan Mourich, Patrick Iversen, Dwight Weller
  • Publication number: 20060240032
    Abstract: A composition and method for treating an autoimmune condition are disclosed. The composition includes of an immunomodulating compound composed of a central amino acid core having a plurality of chemical attachment groups, and a plurality of antigenic peptides which are (i) associated with an auto-immune disorder and (ii) attached to the core groups with the same N-terminus to C-terminus orientation. The compound is carried in a pharmaceutically acceptable carrier. An exemplary compound has an octomeric polylysine core and eight antigenic peptides, such as the peptides identified by SEQ ID NOS: 1-11, attached thereto. The compound is effective in treating an autoimmune disorder, by administering to a subject in need of the treatment, a pharmaceutically effective amount of the compound.
    Type: Application
    Filed: March 30, 2006
    Publication date: October 26, 2006
    Inventors: David Hinrichs, Dan Mourich, Patrick Iversen
  • Publication number: 20050234002
    Abstract: A method and composition for inducing human dendritic cells to a condition of reduced capacity for antigen-specific activation of T cells, and, in mature dendritic cells, increased production of extracellular IL-10 is disclosed. A population of dendritic cells is exposed to a substantially uncharged antisense compound containing 12-40 subunits and a base sequence effective to hybridize to an expression-sensitive region of a preprocessed or processed human CD86 transcript identified, in its processed form, by SEQ ID NO:33, to form a duplex structure between said compound and transcript having a Tm of at least 45° C. Formation of the duplex blocks expression of full-length CD86 in said cells, which in turn leads to reduced capacity for antigen-specific activation of T cells, and, in mature dendritic cells, increased production of extracellular IL-10.
    Type: Application
    Filed: January 21, 2005
    Publication date: October 20, 2005
    Inventors: Dan Mourich, Patrick Iversen
  • Publication number: 20050222068
    Abstract: A method and conjugate for selectively targeting activated hematopoietic cells, e.g., macrophage or T-lymphocyte cells, are disclosed. The conjugate is composed of a substantially uncharged antisense compound targeted against HIV, and a reverse TAT (rTAT) polypeptide coupled covalently to the antisense compound. The rTAT polypeptide is effective to produce selective uptake of the conjugate into activated, HIV-infected cells, e.g., activated, HIV-infected macrophage and T-lymphocyte cells. An exemplary embodiment of the invention provides an antisense compound directed to the HIV Vif gene, causing the production of defective HIV virions in an infected individual.
    Type: Application
    Filed: October 21, 2004
    Publication date: October 6, 2005
    Inventors: Dan Mourich, Patrick Iversen, Richad Bestwick
  • Publication number: 20050203041
    Abstract: A method and conjugate for selectively killing antigen-activated T cells are disclosed. The conjugate is composed of a substantially uncharged antisense compound targeted against the human cFLIP protein, and a reverse TAT (rTAT) polypeptide coupled covalently to the antisense compound. The rTAT polypeptide is effective to produce selective uptake of the conjugate into antigen-activated T cells, relative to the uptake of the conjugate into non-activated T cells. The cFLIP antisense compound causes activation induced cell death (AICD) of activated lymphocytes. The method is useful in treating transplantation rejection and autoimmune conditions.
    Type: Application
    Filed: September 22, 2004
    Publication date: September 15, 2005
    Inventors: Dan Mourich, Hong Moulton, David Hinrichs, Patrick Iversen